Adrenomed AG participates in three upcoming conferences

Hennigsdorf (Germany), March 12, 2019 – Adrenomed AG, the vascular integrity company, announced today its participation in three upcoming conferences in Europe. Adrenomed representatives will be available for one-on-one meetings at these events.

12^th Berlin Conference on Life Sciences, Novel Antimicrobials and AMR Diagnostics 2019
March 14 – 15, 2019, Radisson Blu Hotel, Berlin, Germany
https://amr-conference.com/home/

39^th International Symposium on Intensive Care and Emergency Medicine (ISICEM)
March 19 – 22, 2019, Square – Brussels Meeting Center, Brussels, Belgium
Prof. Dr. Peter Pickkers, Radboud University, Department of Intensive Care, Nijmegen, The Netherlands, will give a talk “The adrenomedullin antibody Adrecizumab”, in the session “New therapies for Sepsis”, on 21 March, 8:30 – 8:45 AM CET, Salle M (Bozar).
https://www.intensive.org/1/main.asp

BIO-Europe^® Spring 2019
March 25 – 27, 2019, Messe Wien Exhibition and Congress Center, Vienna, Austria
Dr. Frauke Hein, Chief Business Officer of Adrenomed, will give a company presentation on March 27, 9:30 AM CET, room Schubert 5 (level 1).
https://ebdgroup.knect365.com/bioeurope-spring/

About Adrenomed
Adrenomed AG is a German privately-financed, clinical stage biopharmaceutical company. Adrenomed´s mission is to rescue vascular integrity in order to save the lives of critically ill patients with limited treatment options. Founded in 2009 by a management team with decades of in-depth experience in sepsis and deep knowledge in diagnostics and drug development, the Company’s lead product candidate Adrecizumab is a clinical-stage, first-in-class monoclonal antibody. Adrecizumab targets the vasoprotective peptide Adrenomedullin, an essential regulator of vascular integrity. Adrecizumab is currently under clinical evaluation in a biomarker-guided, double-blinded, placebo-controlled, randomized, multicenter proof-of-concept Phase II study with 300 patients suffering septic shock. Excellent safety and tolerability were demonstrated in two Phase I trials.